Panax Ginseng : Age-Related Cognitive Decline
C エビデンス 小規模研究からのエビデンスは限られていますが、いくつかの肯定的なシグナルがあります。Multiple RCTs with mixed but generally positive results for cognitive function. Evidence is not yet convincing for dementia prevention, but acute cognitive enhancement effects are supported by several trials.
結論
Multiple RCTs with mixed but generally positive results for cognitive function. Evidence is not yet convincing for dementia prevention, but acute cognitive enhancement effects are supported by several trials.
Key Study Findings
対象集団: None
対象集団: Alzheimer's disease patients (review)
対象集団: None
対象集団: healthy adults
対象集団: None
Key Statistics
15
研究数
1500
参加者数
Mixed
グレード
Referenced Papers
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 200-400 mg/day standardized to 4-7% ginsenosides
上限量: Not established; up to 3,000 mg/day used short-term
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
推奨摂取タイミング: Morning; cycling recommended (8 weeks on, 2 weeks off)
Safety & Side Effects
報告されている副作用
- ⚠ Insomnia
- ⚠ Headache
- ⚠ Gastrointestinal discomfort
- ⚠ Changes in blood pressure
- ⚠ Rare: hypoglycemia
既知の相互作用
- ● Anticoagulants and antiplatelet drugs
- ● Antidiabetic drugs (may lower blood sugar)
- ● MAO inhibitors (may potentiate effects)
- ● Stimulants (additive stimulatory effects)
耐容上限摂取量: Not established; up to 3,000 mg/day used short-term
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Panax Ginseng help with Age-Related Cognitive Decline?
How much Panax Ginseng should I take for Age-Related Cognitive Decline?
Are there side effects of Panax Ginseng?
How strong is the evidence for Panax Ginseng and Age-Related Cognitive Decline?
Related Evidence
に関する他の成分: Age-Related Cognitive Decline
Panax Ginseng 他の症状・状態について
References
- [1] Rarchita Sharma et al.. Nutr Neurosci. 2025. Advanced nutraceutical approaches to Parkinson's disease: bridging nutrition and neuroprotection. doi:10.1080/1028415X.2025.2469170 PubMed
- [2] Jingyi Li et al.. Psychopharmacology (Berl). 2025. Ginsenoside Rg1 alleviates PCPA-induced insomnia by inhibiting NLRP3 inflammasome activation and pyroptosis through the Nrf2/HO-1 pathway in mice. doi:10.1007/s00213-025-06828-5 PubMed
- [3] Prabhash Nath Tripathi et al.. Degener Neurol Neuromuscul Dis. 2024. Review of Pharmacotherapeutic Targets in Alzheimer's Disease and Its Management Using Traditional Medicinal Plants. doi:10.2147/DNND.S452009 PubMed
- [4] John E Lewis et al.. J Clin Transl Res. 2021. The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review. PubMed
- [5] Cindy Crawford et al.. J Altern Complement Med. 2021. Dietary Supplement Ingredients for Optimizing Cognitive Performance Among Healthy Adults: A Systematic Review. doi:10.1089/acm.2021.0135 PubMed
- [6] Andrea Brioschi Guevara et al.. Alzheimers Res Ther. 2021. Protocols for cognitive enhancement. A user manual for Brain Health Services-part 5 of 6. doi:10.1186/s13195-021-00844-1 PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。